Skip to main content

Table 2 Laboratory data of Gitelman-like syndrome patients after cisplatin treatment.

From: Gitelman-like syndrome after cisplatin therapy: a case report and literature review

Ref. Age/Sex Type of Cancer Cisplatin dose (mg/m2) K+ (mEq/l) Mg++ (mg/dl) FEMg (%) FECa (%) GFR (ml/m/1.73 m2) Persist (yrs)
1988 (3) 22/M Testicular 459–954¤ 3.4–3.9ψ 1.4 8.9 0.9 88 2–6¤
1988 (3) 36/M Testicular 459–954¤ 3.4–3.9ψ 1.2 8.9 0.9 100 2–6¤
1988 (3) 39/M Testicular 459–954¤ 3.4–3.9ψ 1.1 8.9 0.9 117 2–6¤
1988 (3) 25/M Testicular 459–954¤ 3.4–3.9ψ 1.4 8.9 0.9 69 2–6¤
1988 (3) 27/M Testicular 459–954¤ 3.4–3.9ψ 1.1 8.9 0.9 105 2–6¤
1988 (3) 24/M Testicular 459–954¤ 3.4–3.9ψ 1.6 8.9 0.9 85 2–6¤
1990 (4) 8.5/M Neuroblastoma 720 3.4 1.6 5.5 0.2 85 1.5
1990 (4) 11/F Neuroblastoma 1,710 3.7 1.8 3.4 0.1 102 3.5
1990 (4) 8/M Neuroblastoma 630 3.6 1.2 8.3 0.2 79 1
1991 (5) 13* (4 patients) Neuroblastoma Sarcomas 310–1,710¤ 3.2 1.4 4.3 0.42 85 1.5*
Our case 42/F Ovarian No data 3.4 1.3 8.5 0.6 80 20
Mean +/- SD 21.0 + 11.1   872 +280 3.4 +0.1 1.4 +0.2 6.9 +2.2 0.6 +0.3 89 +12 3.8 +4.5
  1. No individual patient data reported.
  2. ¤ Use mean value to represent data for calculation of table mean.
  3. ψ Use lowest value to represent data for calculation of table mean.
  4. ■ Mean value for all patients from the same study.
  5. ♣ Calculated number from figure 1 in ref 5. Mean value of 1986–2004 data.
  6. * Median value for 12 patients with cisplatin therapy in ref 5.